Grant to help Ocata develop new treatment
Ocata Therapeutics of Marlborough has been awarded a federal grant to help pay for further preclinical development of a potential treatment for two forms of lupus, representing a new potential product line, the company announced Monday.
The grant, whose amount was not disclosed, comes from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), according to a statement from Ocata. The company is developing a stem cell-based treatment for systemic lupus erythematosus (SLE) and lupus nephritis (LN). The two forms of the autoimmune disease impact healthy tissue and the kidneys, respectively.
Ocata, formerly Advanced Cell Technology, focuses on the development and commercialization of regenerative medicine and cell therapy technologies. Its most advanced work lies in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration.
The grant “recognizes the promise of our … product as a potential new treatment for disabling autoimmune diseases like lupus nephritis, where there is no cure available today,” said LeRoux Jooste, Ocata’s chief commercial officer and senior vice president of business development.
WBJ Web Partners
Most Recent
Most Recent
0 Comments